Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1 1

Status

Completed 3Terminated 2Recruiting 2Withdrawn 1Suspended 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 1Inflammation 1Fatigue 1Colorectal Neoplasms 1Cognitive Dysfunction 1Behavior 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Interventional × Riluzole × Clear all
NCT04761614 2025-03-28

Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
13 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT00866840 2024-01-19

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Rutgers, The State University of New Jersey

Phase 2 Completed
13 enrolled 11 charts
Dermatologic

Melanoma

NCT02796755 2021-04-14

Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation

Emory University

Phase 4 Completed
30 enrolled 10 charts

Behavior, Fatigue, Inflammation, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡